Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Poplar Therapeutics

Request full access

Next-generation anti-IgE antibody therapy for atopic diseases

Boston, United StatesBiotech & Life Sciences

About Poplar Therapeutics

Poplar Therapeutics, Inc. is a clinical-stage immunology company that launched in January 2026, after previously being known as Phylaxis Bioscience. The company was founded by healthcare investor Tony Yao, M.D., Ph.D., who now serves as the Chief Scientific Officer. In January 2026, Poplar announced a $50 million Series A financing round led by SR One, Vida Ventures, and Platanus.

The company is focused on developing a new class of anti-IgE therapy to treat atopic conditions such as food allergies, asthma, and atopic dermatitis. Its lead program, PHB-050, is a next-generation anti-IgE antibody currently in Phase 1 clinical trials. PHB-050 features a unique triple-action mechanism designed to block IgE from binding to mast cells, rapidly reduce circulating IgE, and inhibit its production. This approach aims to address the needs of patients with highly elevated IgE levels who are often ineligible for or do not respond to first-generation therapies. The company's goal is to engineer the antibody to direct the IgE-drug complex to the liver for destruction, thereby driving total IgE levels toward zero.

The leadership team includes Chip Baird as President and CEO, who was appointed in October 2025 and previously served as CEO of 2seventy bio. Other key executives are René van der Merwe, M.D., as Chief Medical Officer and Vicki Eatwell as Chief Financial Officer. Poplar Therapeutics anticipates having results from its Phase 1 study in the second half of 2026 and has a cash runway through mid-2027.

Source: Dealroom company data

At a glance

Status
Operational
Employees
16
Open positions
None listed
Industry
Health
Sub-industry
BioTechnology
Sector
Drug Development, Allergy, Immune System
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Mar 2026 $45M $250M SR One · RA Capital Management · ArrowMark Partners · Vida Ventures ↗
SERIES A✓Equity / VC Jan 2026 $50M $200M SR One · Vida Ventures · Platanus Ventures ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Poplar Therapeutics website traffic

Latest recorded traffic for Poplar Therapeutics is 1.6K monthly website visits, up 23.1% over the last three months.

Latest monthly visits1.6K 3-month web change+23.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Poplar Therapeutics in the Boston ecosystem

Live from Dealroom

The Poplar Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States91.7%
🇬🇧 United Kingdom8.3%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Poplar Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Poplar Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.